Novartis AG ADR (NVS)vsVyne Therapeutics Inc (VYNE)
NVS
Novartis AG ADR
$148.34
+1.95%
HEALTHCARE · Cap: $275.95B
VYNE
Vyne Therapeutics Inc
$0.67
+0.53%
HEALTHCARE · Cap: $21.39M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 9925865% more annual revenue ($56.58B vs $570,000). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
VYNE
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.0%
Fair Value
$109.95
Current Price
$148.34
$38.39 premium
Margin of Safety
+36.0%
Fair Value
$0.87
Current Price
$0.67
$0.20 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Revenue surging 54.8% year-over-year
Areas to Watch
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -67.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : VYNE
The strongest argument for VYNE centers on Price/Book, Revenue Growth. Revenue growth of 54.8% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Bear Case : VYNE
The primary concerns for VYNE are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a declining stock while VYNE is a hypergrowth play — different risk/reward profiles.
VYNE carries more volatility with a beta of 1.95 — expect wider price swings.
VYNE is growing revenue faster at 54.8% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 34/100), backed by strong 23.9% margins. VYNE offers better value entry with a 36.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Vyne Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapies for dermatology. The company is headquartered in Bridgewater, New Jersey.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?